Cargando…

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

BACKGROUND: Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Hara, Jamie, Hirst, Ceri, Cabre Marquez, Jose Francisco, Burke, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809751/ https://www.ncbi.nlm.nih.gov/pubmed/33451335 http://dx.doi.org/10.1186/s13023-021-01676-w

Ejemplares similares

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting
por: Chen, Rong, et al.
Publicado: (2022)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
por: Huang, Kun, et al.
Publicado: (2022)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study
por: Ferri Grazzi, Enrico, et al.
Publicado: (2022)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
por: Teare, John M, et al.
Publicado: (2019)

Economic burden of hemophilia B in the US: a systematic literature review
por: Li, Nanxin (Nick), et al.
Publicado: (2019)

Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys
por: Burke, Tom, et al.
Publicado: (2021)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe
por: Burke, Tom, et al.
Publicado: (2021)

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022)

The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017)

Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study
por: Kun, Huang, et al.
Publicado: (2021)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay
por: Wada, Hideo, et al.
Publicado: (2021)

Streptococcus Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort
por: Sayols-Baixeras, Sergi, et al.
Publicado: (2023)

Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022)

New developments in the management of moderate-to-severe hemophilia B
por: Nazeef, Moniba, et al.
Publicado: (2016)

Impact of novel hemophilia therapies around the world
por: Ozelo, Margareth C., et al.
Publicado: (2022)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Desmopressin in moderate hemophilia A patients: a treatment worth considering
por: Loomans, Janneke I., et al.
Publicado: (2018)

Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs
por: Castaman, Giancarlo, et al.
Publicado: (2023)

Sombra 81
por: Nahum, Lucien
Publicado: (1980)

Workshop 81
por: Heagarty, Denise, et al.
Publicado: (1981)

Nested information processing in the living world
por: Wurtz, Tilmann
Publicado: (2021)

Obstectrical Teaching in Europe and America
por: Hirst, B. C.
Publicado: (1909)

Post Splenectomy Fatal Pulmonary Embolism in a Patient with Moderate Hemophilia A
por: Davoodabadi, Abdolhossein, et al.
Publicado: (2011)

The 81 cm retires
Publicado: (1971)

CCM 81.12
Publicado: (1981)

CCM 81-13
Publicado: (1981)

CCM no. 81/14
Publicado: (1981)

CCM 81.09
Publicado: (1981)

CCM 81.16
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_a8fuhbqlcrr5ffhjk5j2gd2685